Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NTRA
HOLDNatera, Inc. · Healthcare · United States · $37.5B · Avg Vol: $379M/d
COMPANY DESCRIPTION
Natera, Inc. is a leading diagnostic company focused on cell-free DNA testing for reproductive health, oncology, and organ transplantation. The company's proprietary technology platforms, including Panorama for non-invasive prenatal testing and Signatera for molecular residual disease detection, establish a significant competitive moat in precision medicine. Its commitment to R&D and clinical validation drives its rapid growth and market leadership in targeted diagnostic areas.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 820.2M | 1.1B | 1.7B | 2.3B | 41.1% | 2.5B | 2.8B | 3.3B | 20.1% |
| EPS | -5.57 | -3.78 | -1.53 | -1.52 | — | -1.58 | -1.71 | -0.20 | — |
| Shares | 111.3M | 119.6M | 132.6M | 139.7M | +25.6% | 143.2M | — | — | — |
| Debt | 446.2M | 442.0M | 187.1M | 214.4M | -21.7% | 240.1M | — | — | — |
| Equity | 705.7M | 765.3M | 1.2B | 1.7B | 34.4% | — | — | — | — |
| Op CF | -431.5M | -247.0M | 135.7M | 215.3M | 58.7% | 211.0M | — | — | — |
| Inv CF | 330.3M | 168.5M | 137.6M | -132.2M | — | — | — | — | — |
| Fin CF | 482.6M | 254.5M | 30.2M | 47.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NTRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NTRA | Natera, Inc.(you) | $37.5B | 51 | HOLD |
| IDXX | IDEXX Laboratories, Inc. | $42.9B | 60 | HOLD |
| WAT | Waters Corporation | $36.8B | 65 | HOLD |
| GH | Guardant Health, Inc. | $19.5B | 47 | HOLD |
| IQV | IQVIA Holdings Inc. | $34.7B | 69 | BUY |
| DHR.MX | Danaher Corporation | $125.1B | 53 | HOLD |
| A | Agilent Technologies, Inc. | $32.5B | 77 | BUY |
| RVTY | Revvity, Inc. | $12.3B | 64 | HOLD |
| ILMN | Illumina, Inc. | $29.4B | 83 | STRONG BUY |
| TMO | Thermo Fisher Scientific Inc. | $211.2B | 55 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%